Zogenix (ZGNX) Produces A Loss For Q4 And Sells Zohydro
Zogenix (ZGNX) recently announced that in Q4, the company lost more than $20 million. Also Zogenix (ZGNX) announced that it would be selling its Zohydro ER business to Pernix Therapeutics (PTX). The sale price on the business is $100 million, with an added $283.5 million for regulatory and sales milestones. As part of the agreement, the part of the sales team and other select employees at Zogenix (ZGNX) will become Pernix Therapeutics employees (PTX).
Outlook – Overall, this one is a bit shaky. As an investor, I never like to pump my money into a company that’s currently operating as a loss. In my opinion, this one might just be a sinking ship and I won’t be hanging around with the captain.
Cytori (CYTX) Therapeutics Stock Down Following Impressive Gains
Cytori (CYTX) Therapeutics bulls were riding high on March 9th and 10th as it seemed as though the rally could only grow stronger. However, today, it seems like the floor has dropped out from under the company’s stock. After two days of relatively impressive gains, just a few hours in the market today have brought the price back to nearly where it was before the start of the rally.
Outlook – While Cytori (CYTX) is definitely a stock to stay away from if you’re afraid of price volatility, I think the company is moving in the right direction for long term growth.
Acadia (ACAD) Stocks Are Flying High On Acquisition Rumors
Yesterday, Acadia (ACAD) stocks hit an all time high as investors speculated about a take over. The rumors started to spread after two investor meetings were called off. While Acadia (ACAD) hasn’t announced exactly why the investor meetings were canceled, the company has been working with Allergan (AGN) to develop a treatment for Schizophrenia, chronic pain, and glaucoma. So, rumors are spreading that Allergan (AGN) may be working to take over Acadia (ACAD).
Outlook – While I wouldn’t buy the stock at the current inflated rate, I wouldn’t necessarily sell it either. The thought of an acquisition always peaks my interest; so, I’ll be watching this one closely and reporting any developments I find in the story.
MannKind (MNKD) Stocks Are Up For The Second Day In A Row
There has been quite a bit volatility with MannKind (MNKD) lately that has sparked a huge debate. MannKind (MNKD) stocks went on a downward spiral following a controversial GS downgrade that lead to a flood of naked shorts. However, it seems as though the stock may have recovered from the Goldman Sachs bashing!
Outlook – While I may have had a different opinion a week ago, I’m starting to really lose faith in Goldman Sachs. With that said, I think the effects of the downgrade are just about over and that what we are seeing is the beginning of steady growth in the stock value.
Gilead Sciences (GILD) Stocks Remain On The Downtrend
Gilead Sciences (GILD) stocks have been struggling for the past 5 days now; falling from over $103 per share to just over $99 per share in the span. Sovaldi is Gilead Sciences (GILD) top prescription drug. However, fears have been mounting about generic competition hitting center stage. Recently, we learned that a and investors fear that sales of the prescription drug will drop.
Outlook – Based on recent developments in generic competition to Sovaldi, I’d have to say that the outlook for this one isn’t great. While I wouldn’t back out just yet, I wouldn’t be jumping in head first either.
What Are Your Thoughts?
Where do you think the stocks mentioned here are headed? Let us know in the comments below!